Do you have idiopathic gastroparesis?
Do you have idiopathic gastroparesis?
If so, consider joining Envision GI study, an idiopathic gastroparesis clinical trial researching an investigational delayed gastric emptying treatment option.
If so, consider joining Envision GI study, an idiopathic gastroparesis clinical trial researching an investigational delayed gastric emptying treatment option.
WHAT IS THE ENVISION GI STUDY?
The Envision GI study is a clinical research study for people who have been diagnosed with idiopathic gastroparesis.
The main purpose of this study is to find out how well the study medication (CIN-102, deudomperidone) improves the symptoms associated with idiopathic gastroparesis.
WHO CAN JOIN THE STUDY?
You may be able to join the study if you meet the following requirements:
✅ Age 18 or older
✅ Confirmed diagnosis of idiopathic gastroparesis
✅ Gastrointestinal symptoms within the last 6 months such as:
- Nausea or vomiting after eating
- Feeling too full after eating
- Bloating
- Throat or stomach pain
Other criteria apply. Talk to your doctor to learn more.
ABOUT THE STUDY MEDICATION
What is the study medication?
The study medication, called CIN-102 or deudomperidone, is a new form of domperidone. Domperidone is used in some countries as a treatment for gastroparesis symptoms as well as issues with the stomach, such as nausea and vomiting. However, domperidone is not available in the US due to the potential for serious side effects. You will have the opportunity to review the potential benefits and risks of the study medication before deciding to participate.
Deudomperidone is made by slightly changing domperidone. It is expected to have similar benefits with fewer side effects. However, more research is needed.
Will I receive the study medication?
Participants will be assigned at random (like the flip of a coin) to receive either the study medication (CIN-102) or placebo (no active ingredients).
What is an “investigational medicine?”
Investigational means the study medication is not approved by regulatory authorities like the US Food and Drug Administration (FDA), and it can only be used in clinical research studies like the Envision GI study.